Qinghai Spring Medicinal Resources Technology Co., Ltd.

SHSE:600381 Lagerbericht

Marktkapitalisierung: CN¥1.6b

Qinghai Spring Medicinal Resources Technology Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Qinghai Spring Medicinal Resources Technology's earnings have been declining at an average annual rate of -22.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.9% per year.

Wichtige Informationen

-22.4%

Wachstumsrate der Gewinne

-22.7%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie10.9%
Wachstumsrate der Einnahmen5.9%
Eigenkapitalrendite-25.0%
Netto-Marge-114.6%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Jun 24
Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 26% Cheaper Price Remains In Tune With Revenues

May 09
Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 26% Cheaper Price Remains In Tune With Revenues

Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 27% Price Boost Is Out Of Tune With Revenues

Mar 12
Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 27% Price Boost Is Out Of Tune With Revenues

Aufschlüsselung der Einnahmen und Ausgaben

Wie Qinghai Spring Medicinal Resources Technology Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

SHSE:600381 Einnahmen, Ausgaben und Erträge (CNY Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 24251-28822715
30 Jun 24245-27723215
31 Mar 24242-26623911
31 Dec 23214-26823412
30 Sep 23192-28223112
30 Jun 23162-28921712
31 Mar 23141-29321312
31 Dec 22160-28821511
30 Sep 22175-26424210
30 Jun 22186-2482248
31 Mar 22183-2632249
31 Dec 21128-24917710
30 Sep 21143-27612410
30 Jun 21138-30513814
31 Mar 21132-31112713
31 Dec 20124-32013112
30 Sep 20128-6910811
30 Jun 20135-611175
31 Mar 20174-201145
31 Dec 1923461164
30 Sep 19248-251536
30 Jun 19277-111584
31 Mar 19305331603
31 Dec 18333681473
30 Sep 183581861031
30 Jun 18441309693
31 Mar 18452316542
31 Dec 17471311592
30 Sep 17646346561
30 Jun 17671275720
31 Mar 17705260930
31 Dec 167082451160
30 Sep 168762551530
30 Jun 161,1153521670
31 Mar 161,1873651820
31 Dec 151,4023582820
30 Sep 151,4662424150
30 Jun 151,5272254400
31 Mar 151,8442855080
31 Dec 142,0633655100
31 Dec 132,1413375420

Qualität der Erträge: 600381 is currently unprofitable.

Wachsende Gewinnspanne: 600381 is currently unprofitable.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 600381 is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.

Beschleunigtes Wachstum: Unable to compare 600381's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: 600381 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: 600381 has a negative Return on Equity (-25%), as it is currently unprofitable.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren